SCHEMBL7448604

SCHEMBL7448604

CCCCOC(=O)N1CCC(CCO)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.55
POLB P06746 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
GAA P10253 1/20 0.43
GNAI3 P08754 2/20 0.43
GNAO1 P09471 2/20 0.43
GNAI1 P63096 2/20 0.43
CHRM4 P08173 1/20 0.40
THRB P10828 1/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GPR119 Q8TDV5 4/20 0.39
HRH2 P25021 1/20 0.39
HRH1 P35367 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
NOS3 P29474 1/20 0.38
NOS2 P35228 1/20 0.38
MMP2 P08253 1/20 0.38
MMP3 P08254 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28787851 0.93 POLB (0.54) LMNAPOLBSMN1; SMN2GAAGNAI3
SCHEMBL30380124 0.91 LMNA (0.49) LMNAPOLBSMN1; SMN2GAAGNAI3
SCHEMBL11974037 0.91 POLB (0.58) LMNAPOLBSMN1; SMN2GAAGNAI3
SCHEMBL16256877 0.91 LMNA (0.58) LMNAPOLBSMN1; SMN2GAAGNAI3
SCHEMBL725320 0.88 LMNA (0.58) LMNAPOLBSMN1; SMN2GAAGNAI3
SCHEMBL9200805 0.85 GAA (0.57) POLBSMN1; SMN2GAATHRBATM
SCHEMBL27793040 0.85 POLB (0.52) LMNAPOLBSMN1; SMN2GAAGNAI3
SCHEMBL29655416 0.84 LMNA (0.50) LMNAPOLBSMN1; SMN2ATMHRH2
SCHEMBL31282160 0.84 GNAO1 (0.60) LMNAPOLBSMN1; SMN2GAAGNAI3
SCHEMBL4193447 0.84 LMNA (0.51) LMNAPOLBSMN1; SMN2GAAGNAI3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3774804-A1 N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES Novartis AG (CH) 2021-02-17 EP disclosed
EP-3638678-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS Modernatx, Inc. (US) 2020-04-22 EP disclosed
EP-3612536-A1 OXEPINOPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3-KINASE ACTIVITY GlaxoSmithKline Intellectual Property Development Limited (GB) 2020-02-26 EP disclosed
WO-2019186343-A1 N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES NOVARTIS AG (CH) 2019-10-03 WO disclosed
WO-2018232120-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS MODERNATX, INC. (US) 2018-12-20 WO disclosed
WO-2018192864-A1 OXEPINOPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3-KINASE ACTIVITY GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-10-25 WO disclosed
EP-1007051-A4 INTEGRIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2001-08-29 EP disclosed
EP-1007051-A1 INTEGRIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-06-14 EP disclosed
WO-1999006049-A1 INTEGRIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-02-11 WO disclosed